Zasocitinib for psoriasis on the palms and soles
Treatments studied
Part of Skin clinical trials.
This study tests a new pill called zasocitinib for adults with psoriasis on the palms and soles. It aims to see if the pill can reduce the severity of these stubborn patches without serious side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have had psoriasis on your palms and/or soles for at least 6 months
- Have moderate to severe psoriasis on your palms and/or soles, plus some psoriasis on other body areas
- Have tried other treatments (like creams, light therapy, or systemic pills) without success
- Be a candidate for light therapy or systemic therapy
- Not have taken certain biologic medications (like Stelara or Taltz) recently, and must never have taken JAK or TYK2 inhibitors (like Xeljanz or Sotyktu) at all
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a daily pill (zasocitinib) for children and teens with moderate to severe plaque psoriasis that hasn't been controlled by other treatments. It aims to see if the pill can safely improve skin symptoms over a long period.
This study tests an oral medicine called zasocitinib for people with psoriatic arthritis who have not had enough relief from other treatments. It may help reduce joint pain and skin symptoms.
This trial tests an oral medication called zasocitinib for adults with psoriatic arthritis who have not tried biologic medicines before. It aims to see if the drug can improve joint pain, swelling, and skin symptoms.
This study is for people with psoriatic arthritis who have already completed a year-long treatment with zasocitinib or a similar medicine in a previous study. It tests whether continuing to take zasocitinib remains safe and helpful over a longer time.
This trial tests an oral medication called zasocitinib to see if it can help repigment skin in adults with nonsegmental vitiligo. It may be an option for people whose vitiligo covers a moderate amount of their body and who have not had certain recent treatments.
This trial tests a new daily pill called zasocitinib for people with moderate to severe hidradenitis suppurativa (HS) who haven't been helped enough by antibiotics. It aims to reduce painful lumps and abscesses.
Hear when a new Palmoplantar Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.